All In Biotech

Drug Trial Radar · NCT01522976

Azacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia

A Randomized Phase II/III Study of Azacitidine in Combination With Lenalidomide (NSC-703813) vs. Azacitidine Alone vs. Azacitidine in Combination With Vorinostat (NSC-701852) for Higher-Risk Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML)

Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingResults posted on the registryPivotal-lookingRandomized with 282 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

282

Actual

Start

Mar 1, 2012

Primary completion

Jun 1, 2015

Study completion Mar 31, 2027

Sponsor

Sponsor type
NIH
First posted
Feb 1, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This randomized phase II/III trial studies how well azacitidine works with or without lenalidomide or vorinostat in treating patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia. Drugs used in chemotherapy, such as azacitidine, work in different ways to stop the growth of cancer cells, either by killing the cells, stopping them from dividing, or by stopping them from spreading. Lenalidomide may stop the growth of cancer cells by stopping blood flow to the cancer. Vorinostat may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. It is not yet known whether azacitidine is more effective with or without lenalidomide or vorinostat in treating myelodysplastic syndromes or chronic myelomonocytic leukemia.

Conditions

  • Chronic Myelomonocytic Leukemia
  • Chronic Myelomonocytic Leukemia-1
  • Chronic Myelomonocytic Leukemia-2
  • Myelodysplastic Syndrome
  • Myelodysplastic Syndrome With Excess Blasts
  • Myelodysplastic Syndrome With Excess Blasts-1
  • Myelodysplastic Syndrome/Acute Myeloid Leukemia

Interventions

  • AzacitidineDrug

    Given SC or IV

  • Laboratory Biomarker AnalysisOther

    Correlative studies

  • LenalidomideDrug

    Given PO

  • VorinostatDrug

    Given PO

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Response Rate (Phase II)Time frame: Up to 5 years
  2. Overall Survival (Phase III)Time frame: Up to 5 years

Locations

294 sites in 2 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham Cancer Center

    Birmingham, Alabama

  • University of South Alabama Mitchell Cancer Institute

    Mobile, Alabama

  • Mayo Clinic in Arizona

    Scottsdale, Arizona

  • Banner University Medical Center - Tucson

    Tucson, Arizona

  • University of Arizona Cancer Center-North Campus

    Tucson, Arizona

  • John L McClellan Memorial Veterans Hospital

    Little Rock, Arkansas

  • Kaiser Permanente-Deer Valley Medical Center

    Antioch, California

  • City of Hope Comprehensive Cancer Center

    Duarte, California

  • USC / Norris Comprehensive Cancer Center

    Los Angeles, California

  • Kaiser Permanente-Oakland

    Oakland, California

  • Stanford Cancer Institute Palo Alto

    Palo Alto, California

  • Kaiser Permanente-Richmond

    Richmond, California

  • Kaiser Permanente-South Sacramento

    Sacramento, California

  • Kaiser Permanente Sacramento Medical Center

    Sacramento, California

  • Kaiser Permanente-San Francisco

    San Francisco, California

  • Kaiser Permanente-Santa Teresa-San Jose

    San Jose, California

  • Kaiser Permanente-San Rafael

    San Rafael, California

  • Kaiser Permanente Medical Center - Santa Clara

    Santa Clara, California

  • Kaiser Permanente-Santa Rosa

    Santa Rosa, California

  • Sutter Pacific Medical Foundation

    Santa Rosa, California

  • Kaiser Permanente-South San Francisco

    South San Francisco, California

  • Kaiser Permanente-Vallejo

    Vallejo, California

  • Kaiser Permanente-Walnut Creek

    Walnut Creek, California

  • The Medical Center of Aurora

    Aurora, Colorado

  • UCHealth University of Colorado Hospital

    Aurora, Colorado

  • Boulder Community Foothills Hospital

    Boulder, Colorado

  • Penrose-Saint Francis Healthcare

    Colorado Springs, Colorado

  • AdventHealth Porter

    Denver, Colorado

  • Colorado Blood Cancer Institute

    Denver, Colorado

  • Presbyterian - Saint Lukes Medical Center - Health One

    Denver, Colorado

  • Rocky Mountain Cancer Centers-Midtown

    Denver, Colorado

  • Saint Joseph Hospital - Cancer Centers of Colorado

    Denver, Colorado

  • Rocky Mountain Cancer Centers-Rose

    Denver, Colorado

  • Rose Medical Center

    Denver, Colorado

  • Western States Cancer Research NCORP

    Denver, Colorado

  • Mercy Medical Center

    Durango, Colorado

  • Mountain Blue Cancer Care Center - Swedish

    Englewood, Colorado

  • Swedish Medical Center

    Englewood, Colorado

  • Poudre Valley Hospital

    Fort Collins, Colorado

  • Mountain Blue Cancer Care Center

    Golden, Colorado

Showing 40 of 294 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.